Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes.

Gulisano W, Ter-Borch G, Brown P, Feinberg JB, Gonczi M, Hildebrand E, Legere-DeJohn G, Sustarsic R, Sparre T

Journal of diabetes science and technology28 Jun 2026

PMID42366647DOI10.1177/19322968261461530PepBankPUB-42366647

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone12

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Cagrilintide aloneOther designOther
In adults with overweight, obesity or type 2 diabetes, all but one participant completed a simulated injection with the CagriSema dual-chamber pen.
In plain wordsIn a simulated-injection test, all but one adult finished an injection with the CagriSema pen.
Peptide
Cagrilintide
Outcome
Not applicableInjection completion
Study
n = 150
Outcome group
Device usability · Pharmacology
Source sentences
Summary
All but one participant completed the injection successfully.
2 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated the usability of the CagriSema dual-chamber pen, a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of a fixed-dose combination of cagrilintide and semaglutide.
Summary · context
Adults with overweight/obesity (n = 85) or type 2 diabetes (n = 65) performed simulated injections after standardized training.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4236664701
02HumanNot a test of Semaglutide aloneOther designOther
In adults with overweight, obesity or type 2 diabetes, all but one participant completed a simulated injection with the CagriSema dual-chamber pen.
In plain wordsIn adults who did simulated injections with the CagriSema pen, all but one person completed the injection.
Peptide
Semaglutide
Outcome
Not applicableInjection completion
Study
n = 150
Outcome group
Device usability · Pharmacology
Source sentences
Summary
All but one participant completed the injection successfully.
2 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated the usability of the CagriSema dual-chamber pen, a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of a fixed-dose combination of cagrilintide and semaglutide.
Summary · context
Adults with overweight/obesity (n = 85) or type 2 diabetes (n = 65) performed simulated injections after standardized training.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4236664708
03HumanNot a test of Semaglutide aloneOther designOther
In adults with overweight, obesity or type 2 diabetes, median training time with the CagriSema pen was 3 minutes and median time to prepare and inject was 15 seconds.
In plain wordsWith the CagriSema pen, typical training took 3 minutes and typical time to prepare and inject was 15 seconds.
Peptide
Semaglutide
Outcome
Not applicableTraining time and time to prepare and inject
Study
n = 150
Outcome group
Device usability · Pharmacology
Measurements
Median training time
3 minutes
CagriSema pen
Time to prepare and inject
15 seconds
CagriSema pen
Source sentences
Summary
Median training time was 3 minutes, and time to prepare and inject was 15 seconds.
2 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated the usability of the CagriSema dual-chamber pen, a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of a fixed-dose combination of cagrilintide and semaglutide.
Summary · context
Adults with overweight/obesity (n = 85) or type 2 diabetes (n = 65) performed simulated injections after standardized training.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4236664709
04HumanNot a test of Semaglutide aloneOther designOther
In adults with overweight, obesity or type 2 diabetes, all participants (100%) rated the CagriSema pen easy or very easy to use.
In plain wordsIn adults who did simulated injections with the CagriSema pen, everyone rated the pen easy or very easy to use.
Peptide
Semaglutide
Outcome
Not applicableEase of use rating
Study
n = 150
Outcome group
Device usability · Pharmacology
Measurements
Rated easy/very easy to use
100%
CagriSema pen
Source sentences
Summary
Participants rated the device easy/very easy to use (100%)
2 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated the usability of the CagriSema dual-chamber pen, a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of a fixed-dose combination of cagrilintide and semaglutide.
Summary · context
Adults with overweight/obesity (n = 85) or type 2 diabetes (n = 65) performed simulated injections after standardized training.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4236664710
05HumanNot a test of Semaglutide aloneOther designOther
In adults with overweight, obesity or type 2 diabetes, 98.7% of participants rated the CagriSema pen easy or very easy to learn.
In plain wordsIn adults who did simulated injections with the CagriSema pen, almost all rated the pen easy or very easy to learn.
Peptide
Semaglutide
Outcome
Not applicableEase of learning rating
Study
n = 150
Outcome group
Device usability · Pharmacology
Measurements
Rated easy/very easy to learn
98.7%
CagriSema pen
Source sentences
Summary
easy/very easy to learn (98.7%), and an injection with the pen convenient (99.3%).
2 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated the usability of the CagriSema dual-chamber pen, a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of a fixed-dose combination of cagrilintide and semaglutide.
Summary · context
Adults with overweight/obesity (n = 85) or type 2 diabetes (n = 65) performed simulated injections after standardized training.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4236664711
06HumanNot a test of Semaglutide aloneOther designOther
In adults with overweight, obesity or type 2 diabetes, 99.3% of participants rated an injection with the CagriSema pen as convenient.
In plain wordsIn adults who did simulated injections with the CagriSema pen, almost all rated an injection with the pen as convenient.
Peptide
Semaglutide
Outcome
Not applicableConvenience rating
Study
n = 150
Outcome group
Device usability · Pharmacology
Measurements
Rated injection convenient
99.3%
CagriSema pen
Source sentences
Summary
an injection with the pen convenient (99.3%).
2 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated the usability of the CagriSema dual-chamber pen, a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of a fixed-dose combination of cagrilintide and semaglutide.
Summary · context
Adults with overweight/obesity (n = 85) or type 2 diabetes (n = 65) performed simulated injections after standardized training.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4236664712
07HumanNot a test of Cagrilintide aloneOther designOther
In adults with overweight, obesity or type 2 diabetes, median training time for the CagriSema pen was 3 minutes.
In plain wordsLearning to use the CagriSema pen took a median of 3 minutes in this study of adults.
Peptide
Cagrilintide
Outcome
Not applicableTraining time
Study
n: not reported in source
Outcome group
Device usability · Pharmacology
Measurements
Median training time
3 minutes
pen training
Source sentences
Summary
Median training time was 3 minutes
2 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated the usability of the CagriSema dual-chamber pen, a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of a fixed-dose combination of cagrilintide and semaglutide.
Summary · context
Adults with overweight/obesity (n = 85) or type 2 diabetes (n = 65) performed simulated injections after standardized training.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4236664702
08HumanNot a test of Cagrilintide aloneOther designOther
In adults with overweight, obesity or type 2 diabetes, the time to prepare and inject with the CagriSema pen was 15 seconds.
In plain wordsPreparing and giving a simulated injection with the CagriSema pen took 15 seconds in this study of adults.
Peptide
Cagrilintide
Outcome
Not applicableTime to prepare and inject
Study
n: not reported in source
Outcome group
Device usability · Pharmacology
Measurements
Time to prepare and inject
15 seconds
simulated injection
Source sentences
Summary
time to prepare and inject was 15 seconds.
2 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated the usability of the CagriSema dual-chamber pen, a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of a fixed-dose combination of cagrilintide and semaglutide.
Summary · context
Adults with overweight/obesity (n = 85) or type 2 diabetes (n = 65) performed simulated injections after standardized training.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4236664703
09HumanNot a test of Cagrilintide aloneOther designOther
In adults with overweight, obesity or type 2 diabetes, 100% rated the CagriSema pen easy or very easy to use.
In plain wordsAll adults in this study rated the CagriSema pen easy or very easy to use.
Peptide
Cagrilintide
Outcome
Not applicableEase of use rating
Study
n: not reported in source
Outcome group
Device usability · Pharmacology
Measurements
Rated easy/very easy to use
100%
participants
Source sentences
Summary
Participants rated the device easy/very easy to use (100%)
2 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated the usability of the CagriSema dual-chamber pen, a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of a fixed-dose combination of cagrilintide and semaglutide.
Summary · context
Adults with overweight/obesity (n = 85) or type 2 diabetes (n = 65) performed simulated injections after standardized training.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4236664704
10HumanNot a test of Cagrilintide aloneOther designOther
In adults with overweight, obesity or type 2 diabetes, 98.7% rated the CagriSema pen easy or very easy to learn.
In plain wordsAlmost all adults in this study rated the CagriSema pen easy or very easy to learn.
Peptide
Cagrilintide
Outcome
Not applicableEase of learning rating
Study
n: not reported in source
Outcome group
Device usability · Pharmacology
Measurements
Rated easy/very easy to learn
98.7%
participants
Source sentences
Summary
easy/very easy to learn (98.7%), and an injection with the pen convenient (99.3%).
2 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated the usability of the CagriSema dual-chamber pen, a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of a fixed-dose combination of cagrilintide and semaglutide.
Summary · context
Adults with overweight/obesity (n = 85) or type 2 diabetes (n = 65) performed simulated injections after standardized training.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4236664705
11HumanNot a test of Cagrilintide aloneOther designOther
In adults with overweight, obesity or type 2 diabetes, 99.3% rated an injection with the CagriSema pen convenient.
In plain wordsAlmost all adults in this study rated an injection with the CagriSema pen as convenient.
Peptide
Cagrilintide
Outcome
Not applicableConvenience rating
Study
n: not reported in source
Outcome group
Device usability · Pharmacology
Measurements
Rated injection convenient
99.3%
participants
Source sentences
Summary
an injection with the pen convenient (99.3%).
2 context sentences(design, population, supporting numbers)
Summary · context
This study evaluated the usability of the CagriSema dual-chamber pen, a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of a fixed-dose combination of cagrilintide and semaglutide.
Summary · context
Adults with overweight/obesity (n = 85) or type 2 diabetes (n = 65) performed simulated injections after standardized training.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4236664706
12HumanNot a test of Cagrilintide aloneOther designOther
In adults with overweight, obesity or type 2 diabetes, usability results with the CagriSema pen were consistent across populations and unaffected by prior device experience.
In plain wordsIn this study of adults, results for the CagriSema pen were similar across groups and did not depend on past experience with injection devices.
Peptide
Cagrilintide
Outcome
Not applicableConsistency of usability results across populations and prior device experience
Study
n: not reported in source
Outcome group
Device usability · Pharmacology
Source sentences
Summary
Results were consistent across populations and unaffected by prior device experience.
In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.
Report a problemFND-4236664707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 3 to 38Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.